Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Companyâs pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Companyâs pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļāļ·āđāļāļāļĢāļīāļĐāļąāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒ- -
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļ- -
āļāļĩāđāļāļĒāļđāđ- -
āđāļĄāļ·āļāļ- -
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđ- -
āļāļĢāļ°āđāļāļĻ- -
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ- -
āđāļ§āđāļāđāļāļāđ- -
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
Mr. Sherwin Sattarzadeh
Chief Operating Officer
Mr. Sherwin Sattarzadeh
Interim Principal Executive Officer, Chief Operating Officer
Interim Principal Executive Officer, Chief Operating Officer
Ms. Julianne Bruno
Independent Director
Ms. Julianne Bruno
Independent Director
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
Dr. Becker Hewes, M.D.
Chief Medical Officer
Dr. Chris W. Cain, Ph.D.
Independent Director
Mr. Michael (Mike) Landsittel
Mr. Michael (Mike) Landsittel
Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Sherwin Sattarzadeh
Chief Operating Officer
Mr. Sherwin Sattarzadeh
Interim Principal Executive Officer, Chief Operating Officer
Interim Principal Executive Officer, Chief Operating Officer
Ms. Julianne Bruno
Independent Director
Ms. Julianne Bruno
Independent Director
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary